Finanzen von Tenaya Therapeutics Inc (TNYA)TNYATenaya Therapeutics Inc

Evaluating the bottom line, Tenaya Therapeutics, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1882.79%, while the net margin is -3909.28%. These profitability ratios, combined with a Return on Equity (ROE) of -121.86%, provide a clear picture of how effectively TNYA converts its operational activities into shareholder value.

In the context of the broader market, TNYA competes directly with industry leaders such as NRXP and OKUR. With a market capitalization of $163.26M, it holds a leading position in the sector. When comparing efficiency, TNYA's gross margin of 100.00% stands against NRXP's 35.02% and OKUR's N/A. Such benchmarking helps identify whether Tenaya Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Tenaya Therapeutics has shown no revenue for several quarters, with a gross margin of 100% only in the most recent quarters, but this is overshadowed by substantial net losses. The forward P/E ratio is currently at 0, indicating no earnings expected in the near term.